AI assistant
Protagonist Therapeutics, Inc — Director's Dealing 2018
May 17, 2018
31163_dirs_2018-05-17_80b615de-6f08-4f08-b11c-71323a4a7c5d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Protagonist Therapeutics, Inc (PTGX)
CIK: 0001377121
Period of Report: 2018-05-15
Reporting Person: Giraudo Bryan (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-05-16 | Common Stock | P | 10000 | $6.4566 | Acquired | 10000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-15 | Stock Option (right to buy) | $6.45 | A | 24000 | Acquired | 2028-05-14 | Common Stock (24000) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.43 to $6.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: The shares subject to the option shall vest in 36 equal monthly installments from the vesting commencement date of May 15, 2018.